To Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract Patients

Wenzhou Medical University

Status

Unknown

Conditions

Cataract

High Myopia

Treatments

Procedure: PanOptix IOL implantation

Study type

Interventional

Funder types

Other

Identifiers

NCT05042856

ZYY-PanOptix IOL

Details and patient eligibility

About

To evaluate IOL position, clinical outcome of PanOptix in high myopic cataract patients

Full description

A prospective, single center study to evaluate IOL position, clinical outcome of PanOptix in high myopic cataract patients.

The objective of this study to investigate the refractive and visual performance of PanOptix and explore their correlation with ELP change, capsular bending formation, IOL tilt/decentration in high myopic cataract patients.

PanOptix IOL provides good refractive outcomes and visual quality because of few ELP change, fast capsular bending formation and few tilt and decentration in high myopic cataract patients.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients over 18 years old
26 ≤Axial length<30mm, IOL power ≥6D (PanOptix IOL power is available +6D-+30D )
Eyes with corneal astigmatism less than 1.0D (IOLMaster 700, Carl Zeiss Meditec AG)
Eyes with pupil diameter between 3 and 5.5 mm (iTrace, Tracey Technology, Houston, Texas, USA)
Eyes with angle kappa and angle Alpha ≤0.50 mm (iTrace);
Eyes with corneal spherical aberration ≤ 0.50 (Pentacam).

Exclusion criteria

Irregular corneal astigmatism
Serious intraoperative complications, glaucoma, pseudoexfoliation syndrome, uveitis, macular degeneration or other retinal impairment
Moderate-severe dry eye, corneal scarring, amblyopia
Patients who can't cooperate with post-op 3 months follow-up.